Ausgabe 1/2021
Inhalt (12 Artikel)
Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective
Xinrui Yang, He Yin, Richard D. Kim, Jason B. Fleming, Hao Xie
Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis
Xiaoyang Li, Yu Zheng, Fei Yue
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib
Nicola Fazio, Matthew Kulke, Brad Rosbrook, Kathrine Fernandez, Eric Raymond
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
Jean-Pierre Delord, Antoine Italiano, Ahmad Awada, Philippe Aftimos, Nadine Houédé, Céleste Lebbé, Celine Pages, Thierry Lesimple, Monica Dinulescu, Jan H. M. Schellens, Suzanne Leijen, Sylvie Rottey, Vibeke Kruse, Richard Kefford, Sandrine Faivre, Carlos Gomez-Roca, Armin Scheuler, Giorgio Massimini, Eric Raymond
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Céleste Lebbé, Antoine Italiano, Nadine Houédé, Ahmad Awada, Philippe Aftimos, Thierry Lesimple, Monica Dinulescu, Jan H. M. Schellens, Suzanne Leijen, Sylvie Rottey, Vibeke Kruse, Richard Kefford, Eric Raymond, Sandrine Faivre, Celine Pages, Carlos Gomez-Roca, Armin Schueler, Samantha Goodstal, Giorgio Massimini, Jean-Pierre Delord
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
Domenica Lorusso, Giuseppa Maltese, Ilaria Sabatucci, Sara Cresta, Cristina Matteo, Tommaso Ceruti, Maurizio D’Incalci, Massimo Zucchetti, Francesco Raspagliesi, Cristina Sonetto, Valentina Sinno, Dominique Ronzulli, Serena Giolitto, Filippo de Braud
Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
Jenny Zheng, Yanke Yu, Chandrasekar Durairaj, Véronique Diéras, Richard S. Finn, Diane D. Wang
The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
Anna Buder, Maximilian J. Hochmair, Martin Filipits
Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
François Laliberté, Monika Raut, Xiaoqin Yang, Guillaume Germain, Akash Nahar, Kaushal D. Desai, Sean D. MacKnight, Shuvayu S. Sen, Mei Sheng Duh
Developing Symptom Lists for People with Cancer Treated with Targeted Therapies
Samantha C. Sodergren, Sally J. Wheelwright, Deborah Fitzsimmons, Fabio Efficace, Mirjam Sprangers, Peter Fayers, Amelie Harle, Heike Schmidt, Andrew Bottomley, Anne-Sophie Darlington, Charlotte Benson, Anne Bredart, Leopold Hentschel, Juan Ignacio Arraras, Georgios Ioannidis, Michael Leahy, Iwona Lugowska, Ourania Nicolatou-Galitis, Duska Petranovic, Gudrun E Rohde, Vasilis Vassiliou, Colin D. Johnson
Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers
Catherine H. Watson, Gloria Broadwater, Janice Wong, Daniel Spinosa, Mary Katherine Montes de Oca, Michael Datto, Michelle Green, Christopher Hubbard, Matthew McKinney, Shannon J. McCall, Laura J. Havrilesky, John H. Strickler, Andrew Berchuck, Kyle C. Strickland, Rebecca A. Previs